The funding will support regulatory certification and the commercial launch of rapid tests for Lyme disease and sexually transmitted infections.
En Carta Diagnostics, a startup developing molecular diagnostics for at-home use, has secured €5 million (approximately $5.8 million) in a first closing of financing. The funds will be used to advance regulatory certification in Europe and the US, scale industrialization, and launch commercial products starting with early Lyme disease detection.
The financing includes €3 million in equity led by Blue Forest Ventures, with participation from Ring Capital, CentraleSupélec Venture, 50 Partners Health, and a group of business angels. An additional €2 million in non-dilutive funding was provided by Bpifrance and other partners.
In January 2026, the company received Breakthrough Device Designation from the Food and Drug Administration (FDA) for its EC Pocket Lyme test for early detection of Borrelia bacteria, which causes Lyme disease. This status provides an accelerated regulatory pathway to the US market. En Carta Diagnostics is currently conducting clinical trials for its flagship product in Boston and Bialystock, Poland.
The company’s technology is a rapid point-of-need molecular diagnostic platform that uses aptamers to bind with high affinity and specificity to a predetermined target. The system is designed to deliver results in 30 minutes in an affordable cassette format. Following the Lyme disease launch, the company plans to introduce tests for sexually transmitted infections (STIs), including chlamydia and gonorrhea.
En Carta Diagnostics has established a €13 million commercial partnership with AAZ to market rapid molecular tests for STIs in Europe. The company also partnered with Circum Medical for high-volume manufacturing of the hardware components.
“From FDA Breakthrough Designation to a €13M commercial partnership, and now €5M in financing, En Carta is delivering. Our next milestone is getting our two products, a rapid molecular diagnostic for Borrelia, the bacteria responsible for Lyme disease, and an STI screening test, into the hands of patients and clinicians across Europe and the US. This first closing brings us closer to our mission of transforming access to testing,” says Guillaume Horreard, co-founder and CEO, En Carta Diagnostics, in a release.
According to the Centers for Disease Control and Prevention, Lyme disease is the most prevalent vector-borne disease in the Northern Hemisphere, with cases increasing 22.5% annually. Existing diagnostic tools often cannot detect the infection until weeks after a tick bite, which is when clinicians and patients need answers most, according to the company.
“Improving access to fast, reliable diagnosis is essential to delivering better healthcare outcomes. En Carta Diagnostics’ technology has the potential to significantly enhance early detection and bring high-quality molecular testing closer to patients,” says Max Narr, co-founder and general partner, Blue Forest Ventures, in a release.
Photo caption: EC Pocket Lyme test
File photo/provided En Carta Diagnostics
